Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Mucosal correlates of protection in HIV-1-exposed sero-negative persons.

Shen R, Smith PD.

Am J Reprod Immunol. 2014 Aug;72(2):219-27. doi: 10.1111/aji.12202. Epub 2014 Jan 16. Review.

2.

Towards an effective genital herpes vaccine: past lessons and future prospects.

Halford WP.

Future Virol. 2007 Jan 1;2(1):1-6. No abstract available.

3.

Sieve analysis in HIV-1 vaccine efficacy trials.

Edlefsen PT, Gilbert PB, Rolland M.

Curr Opin HIV AIDS. 2013 Sep;8(5):432-6. doi: 10.1097/COH.0b013e328362db2b. Review.

4.
5.

Neutralizing antibodies to HIV-1 induced by immunization.

McCoy LE, Weiss RA.

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.

6.

Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT.

J Biol Chem. 2012 Feb 17;287(8):5673-86. doi: 10.1074/jbc.M111.317776. Epub 2011 Dec 13.

7.

Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques.

Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman RG, Estes JD, Derdeyn CA, Silvestri G.

J Clin Invest. 2011 Nov;121(11):4433-45. doi: 10.1172/JCI46023. Epub 2011 Oct 17.

8.

Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.

Agwale SM, Forbi JC, Notka F, Wrin T, Wild J, Wagner R, Wolf H.

PLoS One. 2011;6(8):e23233. doi: 10.1371/journal.pone.0023233. Epub 2011 Aug 4.

9.

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.

PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.

10.

How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Klasse PJ, Sanders RW, Cerutti A, Moore JP.

AIDS Res Hum Retroviruses. 2012 Jan;28(1):1-15. doi: 10.1089/AID.2011.0053. Epub 2011 May 20. Review.

11.

Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Bhattacharyya S, Rajan RE, Swarupa Y, Rathore U, Verma A, Udaykumar R, Varadarajan R.

J Biol Chem. 2010 Aug 27;285(35):27100-10. doi: 10.1074/jbc.M110.152272. Epub 2010 Jun 17.

12.

IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):445-58. doi: 10.1089/aid.2009.0223.

13.

HIV-1 vaccine development after STEP.

Barouch DH, Korber B.

Annu Rev Med. 2010;61:153-67. doi: 10.1146/annurev.med.042508.093728. Review.

14.

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, Durso RJ, Parsons TF, Maddon PJ, Moore JP, Olson WC.

Vaccine. 2009 Aug 13;27(37):5120-32. doi: 10.1016/j.vaccine.2009.06.037. Epub 2009 Jun 28.

15.

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Korber BT, Letvin NL, Haynes BF.

J Virol. 2009 Sep;83(17):8300-14. doi: 10.1128/JVI.00114-09. Epub 2009 May 13. Review. No abstract available.

16.

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.

Virology. 2009 Jun 20;389(1-2):108-21. doi: 10.1016/j.virol.2009.04.001. Epub 2009 May 2.

17.

Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.

Laird ME, Igarashi T, Martin MA, Desrosiers RC.

J Virol. 2008 Nov;82(22):11054-65. doi: 10.1128/JVI.01341-08. Epub 2008 Sep 3. Erratum in: J Virol. 2009 Feb;83(4):2055.

18.

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.

Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP.

PLoS Pathog. 2007 Nov;3(11):e169.

19.

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, Vainshtein J, Li Y, Sodroski J, Kwong PD, Mascola JR, Wyatt R.

J Virol. 2007 Jun;81(11):5579-93. Epub 2007 Mar 14.

20.

Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.

Horton H, Havenar-Daughton C, Lee D, Moore E, Cao J, McNevin J, Andrus T, Zhu H, Rubin A, Zhu T, Celum C, McElrath MJ.

J Virol. 2006 Oct;80(19):9779-88.

Supplemental Content

Support Center